MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Core Solutions, a leader in AI-powered solutions for behavioral health and development, has introduced Cx360 Enterprise: The Intelligent Care Record, a platform designed to modernize data management and clinical workflows in behavioral health settings. The system integrates artificial intelligence to help providers capture, organize, and analyze patient information more effectively. The platform is intended to support clinical decision-making, streamline documentation, and improve coordination across care teams. Focused on behavioral health, the platform integrates AI to record and reflect on how care is delivered to individuals, providing healthcare workers with effective ways to manage and configure workflows as well as gain valuable and ethical insights.
Core Solutions focuses on electronic health record (EHR) systems for behavioral health organizations. The new offering is designed to address challenges such as fragmented data, manual processes, and the need for more actionable insights in patient care. The company said, "The Intelligent Care Record brings forward insight in a way that is usable, transparent, and aligned with real clinical workflows, which ultimately supports better care and stronger organizational performance."
The Intelligent Care Record is also intended to support compliance and reporting requirements, which are often complex in behavioral health environments. Healthcare providers are increasingly adopting AI-enabled tools to improve care delivery and operational efficiency.
Posted by MedCloudInsider Editors on 04/13/20260 comments
Ada Health, a clinical expertise and AI insights-driven service provider, announced it has secured a patent for a clinical layer designed to make large language models safer for use in healthcare applications. The technology, Ada's hybrid clinical AI architecture, acts as an intermediary between AI models and clinical use cases, applying medical validation, safety checks, and contextual controls to AI-generated outputs. The goal is to reduce risks associated with using general-purpose language models in clinical decision support and patient interactions. Ada's reasoning engine acts as a guardrail to improve accuracy and preserve rigor, offering a fully auditable clinical reasoning system.
Ada Health focuses on digital health tools that support symptom assessment and care guidance. The patented approach is intended to ensure that AI systems operate within medically appropriate boundaries and align with clinical standards. Healthcare organizations are increasingly exploring generative AI, but concerns remain around accuracy, safety, and regulatory compliance. The patent allows Ada to extend its hybrid approach across pharma and healthcare systems where safety and explainability are of utmost importance.
Posted by MedCloudInsider Editors on 04/13/20260 comments
Clinical AI, a healthcare technology company developing AI solutions to improve clinical trial execution, has announced the launch of its MAIA Prescreening solution on the Google Cloud Marketplace, targeting improved efficiency in clinical trial recruitment. The launch enables healthcare organizations to deploy AI-driven patient screening workflows directly through Google Cloud. The platform uses artificial intelligence to analyze patient data and identify candidates who may qualify for clinical studies. By automating prescreening, the system is designed to help research organizations reduce manual review processes and accelerate enrollment timelines.
MAIA Prescreening integrates with healthcare data systems to evaluate patient eligibility based on study criteria. The platform also supports interactive virtual assistants and avatar deployments, trial simulations, financial document review, language translation and lab information management systems. The solution is intended to support faster identification of potential participants while improving accuracy in matching patients to trials. Clinical trial recruitment remains a significant challenge for healthcare organizations, often delaying research timelines and increasing costs.
Posted by MedCloudInsider Editors on 04/06/20260 comments
GC Biopharma, a biopharmaceutical company focused on manufacturing plasma derivatives, announced a new technology designed to improve the safety profile of intravenous immunoglobulin (IVIG) therapies by detecting prothrombotic impurities. The method enhances its ability to identify trace impurities that may increase the risk of blood clotting in patients receiving IVIG treatments. These therapies are widely used to treat immune deficiencies and autoimmune conditions, making safety a critical concern in manufacturing and quality control. The enhanced assay incorporates a selective IgG Blocker, suppressing non-specific protein reactions ensuring a precise measurement of FXI regardless of the IgG concentration.
GC Biopharma said the detection technology is intended to strengthen product consistency and reduce potential adverse effects associated with thrombotic events. The approach focuses on improving analytical precision during the production process. Biopharmaceutical manufacturers are increasingly investing in advanced quality control technologies to meet regulatory standards and ensure patient safety.
Posted by MedCloudInsider Editors on 04/06/20260 comments
Lunit, a leader in clinical AI-cancer diagnostics, and CellCarta, a global CRO laboratory, announced a strategic collaboration aimed at accelerating the use of artificial intelligence in digital pathology for companion diagnostic (CDx) development. The partnership will combine Lunit’s AI-based image analysis technology with CellCarta’s laboratory and biomarker services. The goal is to support pharmaceutical companies in developing companion diagnostics that help match patients with targeted therapies based on biomarker data. The collaboration aims to integrate Lunit SCOPE AI digital pathology products with CellCarta workflows to support biomarker strategy, image analysis and CDx readiness.
Digital pathology involves analyzing tissue samples using high-resolution imaging and computational tools. By applying AI models to these images, the companies aim to improve the identification of disease patterns and biomarkers relevant to treatment decisions. Companion diagnostics play a growing role in precision medicine, particularly in oncology, where therapies are increasingly tailored to specific patient characteristics. Under the collaboration, initial focus areas include de-risking, translational and clinical workflows, platform-agnostic deployment and a real-world global pilot.
Posted by MedCloudInsider Editors on 03/30/20260 comments
Atlantic Health, a leading not-for-profit health care system, is using artificial intelligence agents from Artera, an agentic healthcare company, to improve colonoscopy screening rates and address gaps in preventive care. The AI agents are designed to engage patients through automated outreach, helping identify individuals due for screening and encouraging them to schedule appointments. The system uses patient data and communication workflows to support follow-ups and reduce missed screenings. Preparation for a colonoscopy can be complex and overwhelming, leading to patient confusion and high cancellation rates. Artera's AI-agents simplify this process with a standardized, AI-driven and digital-first experience.
Colonoscopy screening is a key method for early detection of colorectal cancer, but healthcare providers often face challenges in ensuring patients complete recommended tests. Atlantic Health said the AI-driven approach is intended to improve adherence by streamlining communication and reducing administrative workload. Healthcare systems are increasingly adopting AI tools to support patient engagement and population health initiatives. With automated efficiency, the time spent on manual calls has drastically reduced, allowing healthcare professionals to maximize schedules for high-level patient care.
Posted by MedCloudInsider Editors on 03/30/20260 comments
Perplexity and b.well Connected Health, a data-rich digital health platform, announced a partnership to integrate verified health data into AI-powered search, with the goal of improving the accuracy and personalization of health-related responses. The integration will allow Perplexity’s AI search platform to draw on b.well’s curated health data, which includes clinical records, care information and wellness data. The approach is intended to provide users with more relevant and personalized health insights while maintaining data accuracy.
This integration allows Perplexity users to securely connect medical records, ask questions to receive grounded results based on their own health history, understand lab results, medications and conditions and prepare for appointments while making informed decisions. The experience is focused on patient privacy and control.
b.well focuses on aggregating healthcare data from providers, payers and digital health tools, giving users a unified view of their health information. By combining this data with AI search capabilities, the companies aim to enhance how individuals access and understand health information. AI-driven search tools are increasingly being used to answer health-related questions, raising concerns about accuracy and reliability. The launch builds on b.well's broad strategy to enable next-generation AI-powered health assistants.
Posted by MedCloudInsider Editors on 03/23/20260 comments
Function, a proactive health platform, has expanded its portfolio of AI connectors with a new integration for Perplexity Health, designed to bring health-related insights into enterprise applications. The connector enables organizations to incorporate AI-driven health search capabilities into workflows by linking Perplexity’s platform with Function’s integration layer. The goal is to allow users to access and act on health information within existing systems without switching between tools. The connector is aimed at allowing members to securely connect lab results with clinician-reviewed summaries to Perplexity so their data is available in AI tools as needed.
Function develops connectors that link AI services with enterprise data sources and applications. By adding support for Perplexity Health, the company aims to extend how organizations can use AI-generated insights alongside internal data and workflows. Enterprises are increasingly adopting connector frameworks to integrate AI services with operational systems.
Posted by MedCloudInsider Editors on 03/23/20260 comments
XRlabs, a surgical intelligence company, announced what it said is the first human use of a physical artificial intelligence system integrated with the ORBEYE exoscope, powered by NVIDIA Jetson Thor. The system applies AI models directly within a surgical imaging environment to support real-time analysis during procedures. By running AI at the edge, the platform is designed to process visual data locally, reducing latency and enabling faster insights for clinicians. Future developments planned include intelligent exoscope automation, real-time surgical video integration, intraoperative scene understanding and immersive stereoscopic viewing.
The ORBEYE exoscope is used in surgical settings to provide high-resolution, magnified views of operating fields. By integrating AI into the system, XRLabs allows for enhanced visualization and potential decision support during complex procedures. Healthcare organizations are increasingly exploring AI applications in surgical and clinical environments, particularly those that can operate in real time.
Posted by MedCloudInsider Editors on 03/18/20260 comments
Sartorius, a biopharmaceutical laboratory, has introduced a next-generation platform, the Eveo Cell Therapy Platform, aimed at improving efficiency and scalability in cell therapy production. The platform is designed to integrate key steps in the manufacturing process, helping organizations manage complex workflows involved in developing and producing cell-based therapies. The system focuses on improving process consistency, reducing manual intervention and enabling better control over production environments.
The new platform integrates cell selection, activation, gene modification, expansion, wash and concentration as well as final formulation into a closed system using critical raw materials to bioreactors and separation technologies.
Cell therapy manufacturing presents unique challenges due to the complexity of handling living cells and the need for precise, repeatable processes. Sartorius said the new platform is intended to help biopharmaceutical companies standardize operations while supporting the transition from research to large-scale production. Demand for cell and gene therapies continues to grow as new treatments enter clinical and commercial stages. Sartorius aims to begin with order processing in September 2026, with the first deliveries of the Eveo Platform expected by 2027.
Posted by MedCloudInsider Editors on 03/18/20260 comments
Mentis Care, an AI-driven neuromonitoring company, announced a research collaboration with Emory University aimed at developing artificial intelligence systems that can detect and predict epileptic seizures using multiple types of neurological data. The project will focus on creating channel-agnostic AI models capable of analyzing signals from different monitoring technologies, including electroencephalography and other neurological data sources. The goal is to improve seizure detection accuracy and enable earlier identification of patterns that may indicate an impending seizure. Improvement in even five minutes of warning times for seizure detection is vital for patients, which is the aim behind Mentis Care building the technology powered by AI to solve this.
Researchers say traditional seizure detection systems often depend on specific monitoring channels, which can limit their effectiveness across different clinical environments or patient monitoring devices. AI models designed to analyze diverse signal types could expand how seizure monitoring systems are deployed in hospitals and research settings. The collaboration reflects growing interest in applying machine learning to neurological monitoring and epilepsy care with an ongoing research focus on development, clinical review and regulatory testing.
Posted by MedCloudInsider Editors on 03/16/20260 comments
Caris Life Sciences, a next-gen AI TechBio company, has introduced a new capability within its Caris AI Insights platform designed to help clinicians identify early resistance to platinum-based chemotherapy in ovarian cancer patients (HGSOC). The tool analyzes molecular and genomic data to detect patterns associated with platinum resistance, a common challenge in ovarian cancer treatment. Identifying resistance earlier could help clinicians adjust treatment strategies before the disease progresses. Harnessing AI across comprehensive real-world databases, Caris aims to accelerate biomarker discovery and enhance therapeutic decision-making of more personalized cancer treatments.
Platinum-based chemotherapy remains a standard treatment for many ovarian cancer patients, but resistance often develops, limiting long-term effectiveness. Tools that analyze genomic and biomarker data are increasingly used to guide precision oncology decisions and help physicians select therapies tailored to individual patients. The Caris AI Insights capability is intended to support oncologists by providing insights derived from large-scale molecular profiling data.
Posted by MedCloudInsider Editors on 03/16/20260 comments